112 related articles for article (PubMed ID: 33560216)
1.
Richardson TE; Walker JM
Clin Neuropathol; 2021; 40(4):209-214. PubMed ID: 33560216
[No Abstract] [Full Text] [Related]
2. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas.
Sahm F; Korshunov A; Schrimpf D; Stichel D; Jones DT; Capper D; Koelsche C; Reuss D; Kratz A; Huang K; Wefers AK; Schick M; Bewerunge-Hudler M; Mittelbronn M; Platten M; Hänggi D; Jeibmann A; Unterberg A; Herold-Mende C; Pfister SM; Brandner S; Wick W; von Deimling A
Acta Neuropathol; 2017 Feb; 133(2):325-327. PubMed ID: 28000032
[No Abstract] [Full Text] [Related]
3. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
4. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.
Cimino PJ; Holland EC
Neuro Oncol; 2019 Jun; 21(6):819-821. PubMed ID: 30918961
[No Abstract] [Full Text] [Related]
5. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O
J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563
[TBL] [Abstract][Full Text] [Related]
6. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
7. MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant.
Liu L; Zhang KN; Zhao Z; Li G; Chai RC; Li Z; Liu X; Chen J; Jiang T
Brain Pathol; 2024 May; 34(3):e13198. PubMed ID: 37530224
[TBL] [Abstract][Full Text] [Related]
8. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
10. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
Marker DF; Pearce TM
Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity of CDKN2A deletions in IDH-mutant astrocytoma.
Masui K; Onizuka H; Muragaki Y; Kawamata T; Kurata A; Komori T
Brain Tumor Pathol; 2024 Apr; 41(2):92-95. PubMed ID: 38597998
[No Abstract] [Full Text] [Related]
12. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
13. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age.
Ferris SP; Goode B; Joseph NM; Kline CN; Samuel D; Gupta N; Bollen A; Perry A; Mueller S; Solomon DA
Acta Neuropathol; 2016 Jul; 132(1):153-5. PubMed ID: 27161253
[No Abstract] [Full Text] [Related]
14. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
15. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
Brat DJ; Aldape K; Colman H; Figrarella-Branger D; Fuller GN; Giannini C; Holland EC; Jenkins RB; Kleinschmidt-DeMasters B; Komori T; Kros JM; Louis DN; McLean C; Perry A; Reifenberger G; Sarkar C; Stupp R; van den Bent MJ; von Deimling A; Weller M
Acta Neuropathol; 2020 Mar; 139(3):603-608. PubMed ID: 31996992
[No Abstract] [Full Text] [Related]
16. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
17. Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome.
Galuppini F; Opocher E; Tabori U; Mammi I; Edwards M; Campbell B; Kelly J; Viel A; Quaia M; Rivieri F; D'Avella D; Arcella A; Giangaspero F; Fassan M; Gardiman MP
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):233-239. PubMed ID: 29130549
[No Abstract] [Full Text] [Related]
18. Chaperonin-containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients.
Hu Y; Fu P; Zhao H; Zhang F; Jiang X; Zhao W; Lv P
J Clin Lab Anal; 2021 Sep; 35(9):e23917. PubMed ID: 34312925
[TBL] [Abstract][Full Text] [Related]
19. Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
Roberts KF; Dahiya SM
Neuro Oncol; 2023 Aug; 25(8):1450-1451. PubMed ID: 37097042
[No Abstract] [Full Text] [Related]
20. Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
Osada Y; Saito R; Miyata S; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
Brain Tumor Pathol; 2021 Jul; 38(3):218-227. PubMed ID: 34269949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
